NXS — Next Science Income Statement
0.000.00%
Last trade - 00:00
- AU$99.18m
- AU$86.42m
- $22.18m
- 31
- 22
- 63
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.06 | 3.44 | 8.95 | 11.7 | 22.2 |
Cost of Revenue | |||||
Gross Profit | 3.51 | 2.92 | 6.94 | 9.15 | 16.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 16.6 | 15.6 | 18.4 | 24.4 | 37.7 |
Operating Profit | -12.5 | -12.2 | -9.48 | -12.7 | -15.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14.4 | -11.9 | -9.35 | -12.7 | -16.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.4 | -11.9 | -9.35 | -12.7 | -16.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.4 | -11.9 | -9.35 | -12.7 | -16.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.4 | -11.9 | -9.35 | -12.7 | -16.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.086 | -0.065 | -0.048 | -0.06 | -0.071 |